IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease
The second product of IASO to receive IND approval from the FDA SHANGHAI and NANJING, China and SAN JOSE, Calif., June 17, 2023 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today announced that the U.S. Food and Drug Administration (FDA) … Read more